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In Brief
Understanding how human antibodies
mediate their pro- and anti-inflammatory
activities in vivo has been hampered by a
lack of suitable model systems. Schwab
et al. established a humanized mouse
model of autoimmunity allowing them to
determine the key pathways involved in
human autoantibody and therapeutic IVIg
activity in vivo.
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Immunoglobulin G (IgG) antibodies are major drivers
of autoimmune pathology, but they are also used in
the form of intravenous IgG (IVIg) therapy to sup-
press autoantibody activity. To identify the pathways
underlying human autoantibody and IVIg activity, we
established a humanizedmousemodel of an autoan-
tibody-dependent autoimmune disease responding
to treatment with IVIg preparations. We show that
the human IgG subclass strongly impacts autoanti-
body activity and that the Fc-receptor genotype of
the human donor immune system further modulates
autoantibody activity. Human mononuclear phago-
cytes were responsible for autoantibody activity,
and IVIg therapy was able to suppress disease pa-
thology in an Fc-fragment-dependent manner. While
highly sialylated IgG glycovariants were essential for
IVIg activity, it was independent of the Fc-receptor
genotype and did not result in a general block of acti-
vating or the neonatal Fc-receptor. These findings
may help in the development of strategies to block
autoantibody and enhance therapeutic IVIg activity
in humans.
INTRODUCTION
Immunoglobulin G (IgG) antibodies are critical for preventing
recurrent microbial infections; conversely, they can also cause
major tissue inflammation and destruction if they are present
in the form of self-reactive autoantibodies (Hogarth and Pie-
tersz, 2012; Pincetic et al., 2014). Of note, IgG-dependent auto-
immune pathology can be efficiently suppressed by infusion of
high doses of pooled IgG preparations (intravenous IgG [IVIg]
therapy), demonstrating that IgG can have both pro- and anti-in-
flammatory activities (Pincetic et al., 2014; Schwab and Nim-
merjahn, 2013). While these dual IgG activities are well estab-
lished and used on a daily basis in the clinic, the molecular
and cellular pathways underlying these opposing effector func-
tions in the human immune system remain to be established.
Mouse model systems have helped to elucidate key compo-610 Cell Reports 13, 610–620, October 20, 2015 ª2015 The Authorsnents of these pathways in rodents, such as the critical role of
cellular type I Fc receptors as mediators of therapeutic IgG
and autoantibody-triggered effector functions (Albanesi and
Dae¨ron, 2012; Hogarth and Pietersz, 2012; Smith and Clatwor-
thy, 2010; Takai, 2002). In contrast, the anti-inflammatory and
immunomodulatory activity of IVIg preparations was shown to
depend on type II Fcg receptors, which can directly recognize
certain IgG glycovariants, such as highly sialylated IgG prepara-
tions (Anthony and Nimmerjahn, 2011; Kaneko et al., 2006b;
Massoud et al., 2014; Pincetic et al., 2014). On the other
hand, several studies noted an influence of the mouse genetic
background with respect to the requirement of IVIg sialylation,
urging for further studies investigating the general relevance of
these findings for the genetically outbred human population
(Campbell et al., 2014; Leontyev et al., 2012a, 2012b; Nagel-
kerke et al., 2014). Moreover, the mouse and human antibody
and Fc-receptor systems differ, and a variety of allelic variants
of human Fc-receptors not present in the mouse limit the
possibility of studying human antibody activity in mice in vivo
(Hogarth and Pietersz, 2012; Lux and Nimmerjahn, 2013; Smith
and Clatworthy, 2010). More recently, transgenic mice express-
ing select combinations of human Fc-receptor alleles have
allowed the first insights into how human antibodies interact
with human Fc receptors in vivo (Smith et al., 2012). While these
models represent a major advance, they do not fully recapitulate
the genetic diversity of the human Fc-receptor system and rely
on triggering effector functions through mouse immune cells. As
an alternative to transgenic mice, humanized mouse models, in
which the human immune system is grafted onto immunodefi-
cient mouse backgrounds, such as NOD/SCID/gc or Rag2/gc
knockout mice, have been developed and represent valuable
in vivo model systems to study the interaction of human patho-
gens with the human immune system (Bournazos et al., 2014;
Halper-Stromberg et al., 2014; Horwitz et al., 2013; Shultz
et al., 2012).
With respect to studying human (auto)antibody activity in hu-
manized mice, however, the presence of mouse activating Fcg
receptors, which can interact with different human IgG sub-
classes, represents a major caveat (Lux and Nimmerjahn,
2013; Lux et al., 2014). Thus, IgG effector functions may be
largely mediated by mouse innate immune effector cells and
not by their human counterparts. Moreover, to date, no human-
ized model system of a clinically relevant autoimmune disease
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Figure 1. Impact of Human Autoantibody
Subclass and Fcg-Receptor Alleles on Dis-
ease Activity in Humanized Mice In Vivo
(A) Shown is the residual platelet count 4 hr after
injection of the human IgG1 anti-platelet antibody
(6A6-hIgG1) in non-humanized, hematopoietic
stem cell (HSC) humanized mice at the day of birth
or human peripheral blood leukocyte humanized
(huPBL) NSG-FcRg/ mice at 6–8 weeks of age.
(B) Residual platelet count 4 hr after injection of
equal amounts of the indicated 6A6-human IgG
subclasses in HSC humanized or non-humanized
mice.
(C and D) Depicted are platelet counts in NSG-
FcRg/ mice reconstituted with HSC from indi-
vidual donors with the indicated FcgRIIA-131H/R
and FcgRIIIA-158F/V allelic variants 4 hr after in-
jection of the 6A6-hIgG1 anti-platelet antibody.
(E) Correlation between the amount of blood
circulating human CD33+ myeloid cells and effi-
ciency of 6A6hIgG1-dependent platelet depletion
in mice reconstituted with HSC from individual
donors with the indicated FcgRIIA-131H/R and
FcgRIIIA-158F/V allelic variants. Pearson’s R2
correlation coefficient for detection of linear de-
pendency is indicated.
Horizontal lines indicate the median. Bars indicate
the mean value ± SD. Data from at least two in-
dependent experiments are shown, and statistical
analysis was performed with a Kruskal-Wallis test
and Dunn’s post hoc test. *p % 0.05, **p % 0.01,
***p% 0.001; ns, not significant. See also Figure S1
and Table S1.responding to standard therapies used in human patients is
available. In this study, we report on the generation of a human-
ized mouse model of autoantibody-driven immunothrombo-
cytopenia (ITP), which responds to IVIg infusion. Using this
humanized mouse model, we identify the critical role of the
autoantibody constant region and the human Fcg-receptor
(FcgR) genotype as modulators of human autoantibody activity
in vivo.
RESULTS
Generation of a Humanized Autoimmune Disease Model
One major drawback limiting studies about pathways relevant
for human autoantibody and IVIg activity on the background of
a genetically complex human immune system is the lack of in vivo
models mirroring this heterogeneity. To be able to study human
IgG activity in vivo without the confounding co-engagement of
mouse innate immune effector cells with the capacity to recog-
nize human antibodies via murine Fc receptors, we have recently
established immunodeficient mouse strains (based on the
nonobese diabetic/severe combined immunodeficiency [NOD/
SCID] gc [NSG] or Rag2/gc backgrounds) additionally lackingCell Reports 13, 610–620functional mouse activating Fcg recep-
tors due to a deficiency in the common
FcRg chain (NSG-FcRg/) (Lux et al.,
2014). NSG-FcRg/ mice can be xeno-grafted with a human immune system by injection of human
hematopoietic stem cells (HSCs) during the first 48 hr after birth,
resulting in the presence of all major human immune cells in the
blood and the immigration of human immune cells into peripheral
secondary lymphoid and non-lymphoid organs (Figures S1A–
S1E; Table S1). To establish a model of a clinically relevant auto-
immune disease dependent on human innate immune effector
cells, we made use of the fact that the majority of platelets pre-
sent in humanized mice were still of mouse origin (Figures S1F
and S1G), enabling us to use the variable region of the mouse
platelet-specific autoantibody 6A6 (Nimmerjahn and Ravetch,
2005; Samuelsson et al., 2001), which we grafted on the back-
ground of all four human IgG subclasses. Injection of these auto-
antibodies into humanized mice resulted in a rapid consumption
of platelets in an IgG-subclass-dependent manner (Figures 1A
and 1B). In contrast, no autoantibody activity was observed in
NSG-FcRg/mice transiently reconstituted with human periph-
eral blood leukocytes in the peritoneum or non-humanized mice,
demonstrating the requirement for a fully developed human im-
mune system in transplanted mice and that mouse innate im-
mune effector cells do not contribute to human IgG-mediated
platelet removal (Figure 1A). Consistent with the differential, October 20, 2015 ª2015 The Authors 611
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Figure 2. Human Fcg-Receptor-Positive
Phagocytes Are Critical for Autoantibody
Activity in Humanized Mice
(A) Shown is the relative expression of CD16 and
CD64 on CD33+ cells before (0h) and 2 hr (2h) after
FcgR-blocking antibody treatment.
(B) Depicted is the residual platelet count 4 hr
after application of 100 mg of anti-platelet antibody
6A6-hIgG1 in humanized NSG-FcRg/ mice pre-
treated with FcgR-blocking antibodies either alone
or in combination with 0.6 g/kg human IgG prior to
ITP induction.
(C) Platelet counts 4 hr after 6A6-hIgG1 injection
into humanized NSG-FcRg/ mice pretreated
with PBS or clodronate containing liposomes to
inactivate the human mononuclear phagocytic
network.
(D) Detection of human macrophages (blue stain-
ing) in the liver of individual humanized mice.
Representative pictures of mice being either
negative (left panel) or positive (right panel) for
human CD45+ cells. Mouse cells (red staining)
were detected with an antibody specific for mouse
CD45.1. Numbers identify individual mice (see also
Table S1). Scale bar represents 200 mm.
(E) Depicted are the residual platelet counts
four hours after injection of 6A6-hIgG1 in human-
ized mice being either negative (left panel) or
positive (right panel) for human CD45+ cells in the
liver.
All 6A6-human IgG subclasses were injected at
100 mg per mouse. Horizontal lines indicate the median. Data from at least two independent experiments are shown, and statistical analysis was performed
by using a Kruskal-Wallis and a Dunn’s post hoc test. *p% 0.05, **p% 0.01, ***p% 0.001; ns, not significant.affinities of human IgG subclasses for human FcgRs, only human
IgG1 and IgG3 platelet-specific autoantibodies induced a rapid
reduction of platelet counts from the peripheral blood of human-
ized mice, while similar amounts of IgG2 and IgG4 autoanti-
bodies caused no pathology (Figure 1B) (Bruhns et al., 2009;
Ravetch and Nimmerjahn, 2008).
Effector Pathways Underlying Human Autoantibody
Activity and Impact of Human FcgR alleles
An advantage of this in vivo model is that mice can be reconsti-
tuted with HSCs from donors carrying different allelic com-
binations of activating FcgRs commonly present in the human
population (Table S1). Of special interest, allelic variants of
FcgRIIA, carrying either a histidine or arginine residue at position
131 (FcgRIIA-131H/R), and FcgRIIIA, carrying a phenylalanine or
valine residue at position 158 (FcgRIIIA-158F/V), have been
associated with the severity of autoimmune diseases and thera-
peutic antibody activity (Hogarth and Pietersz, 2012; Nimmer-
jahn, 2006; Takai, 2002). To study this, we collected HSC
samples from 400 human donors and genotyped them for the
presence of different allelic combinations of activating FcgRs.
Using this HSC pool, we generated four different colonies of hu-
manized mice homozygous or heterozygous for the low-affinity
FcgRIIA-131R or the high-affinity FcgRIIA-131H variant in com-
bination with a homozygous low-affinity variant of FcgRIIIA-
158F or in the presence of one high-affinity variant of FcgRIIIA-
158V (Figures 1C and 1D). Consistent with the higher affinity of
the FcgRIIIA158V variant for human IgG1, the presence of this612 Cell Reports 13, 610–620, October 20, 2015 ª2015 The AuthorsFcgRIIIA allele resulted in a higher level of autoantibody activity
(Figure 1C). Conversely, human IgG1-induced thrombocyto-
penia was lower in humanized mice with a homozygous variant
of the low-affinity FcgRIIIA-158F regardless of the presence of
different FcgRIIA alleles (Figure 1D). As human FcgRIIIA shows
a rather restricted expression pattern on human phagocytes
being dominantly present on resident monocytes and macro-
phages but absent from neutrophils, we reasoned that human
mononuclear cells may be the most likely cell type responsible
for autoantibody activity. The level of human monocytes present
in the blood of humanized mice, however, did not directly corre-
late with autoantibody activity (Figure 1E). To obtain more direct
evidence, we blocked immune complex binding to activating
FcgRs (Figures 2A and 2B) and inactivated the human mononu-
clear phagocyte network with clodronate liposomes (Figure 2C).
As both treatments resulted in a loss of autoantibody activity,
this supports the concept that human FcgR-expressing mono-
nuclear cells are the effector cells responsible for platelet deple-
tion, which is consistent with results in classical mouse model
systems and data from one clinical trial in human ITP patients
(Biburger et al., 2011; Clarkson et al., 1986). As liver resident
macrophages were suggested to contribute to platelet destruc-
tion, we screened for rare humanized mice that did not contain
human liver resident macrophages (Coetzee et al., 2000; Heyns
et al., 1980; Schmidt and Rasmussen, 1985; Stratton et al.,
1989). Of note, human autoantibody-dependent platelet deple-
tion was similar whether human liver resident macrophages
were present or not, excluding a major contribution of the liver
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Figure 3. Differential Effect of IVIg on IgG-
Mediated Platelet and B Cell Depletion and
Impact on Human Immune Cells in Human-
ized Mice
(A) Shown is the residual platelet count in human-
ized NSG-FcRg/ mice 4 hr after injection of
100 mg of the chimeric anti-platelet antibody 6A6-
hIgG1. Prior to ITP induction mice were pretreated
with PBS, 2.5 g/kg IVIg or equimolar amounts of
IVIg-derived Fc fragments.
(B) Detection of IgG binding to all human CD45-
positive cells or human CD33-positive myeloid
cells in the peripheral blood of humanized mice 6h
after application of PBS, 2.5 g/kg IVIg or equimolar
amounts of Fc fragments by flow cytometry.
(C) Depicted are the frequencies of human neu-
trophils and B cells in the peripheral blood of
humanized mice before (black bars) and after
treatment with PBS or IVIg.
(D) Representative example of human immune
cells (CD33-positive myeloid cells and CD19-
positive B cells) present in the blood of humanized
mice before and 24 hr after B cell depletion
induced by injection of 10mg rituximab-IgG1
in either the presence or absence (PBS) of a
pretreatment with 2.5 g/kg IVIg 2 hr before ritux-
imab injection. Mice injected with IVIg without
a consecutive rituximab treatment served as
controls.
(E) Quantification of residual humanB cell counts in
the peripheral blood of humanized NSG-FcRg/
mice pretreated with PBS or 2.5 g/kg IVIg 24 hr
after injection of 10 mg rituximab-IgG1.
Horizontal lines indicate the median. Bars indicate
the mean value ± SD. Statistical analysis was
performed with a Mann-Whitney U test. Data from
at least two independent experiments are shown.
See also Figure S2 and Table S2.or liver resident human cells (Figures 2D and 2E). In a similar
manner, a contribution of lung resident macrophages could be
excluded, as human cells were virtually absent from the lungs
of humanized mice at this age (Figure S1D).
Effect of IVIg on Human Immune Cell Subsets and FcgR-
or FcRn-Dependent Effector Pathways
Having established the effectorpathwaysunderlyinghumanauto-
antibody activity, we tested if infusion of human IVIg preparations,
a standard treatment of ITP in human patients, is therapeutically
active in this humanized ITPmodel system (Bussel, 2006; Imbach
et al., 1981). As previous studies suggest that IVIg Fc- or Fab-
dependent pathways may be responsible for IVIg activity in vivo,
we testedboth, intact IVIg and an equimolar preparation of its iso-
lated Fc-fragment (Schwab and Nimmerjahn, 2013). As shown in
Figure 3A, infusion of both 2.5 g/kg IVIg, which falls within the clin-Cell Reports 13, 610–620ically relevant dose of 1–3 g/kg, and an
equimolar amount of the IVIg Fc fragment
was able to block autoantibody activity,
consistent with data from a clinical trial
with ITPpatients andseveralmousemodel
systems (Debre´ et al., 1993; Schwab andNimmerjahn, 2013). Interestingly, infusion of IVIg and, to a smaller
extent, its Fc fragment resulted in a significant binding to virtually
all human cells in the peripheral blood of humanized mice upon
IVIg infusion (Figure 3B). Asbindingwaspresent on FcgR-positive
and FcgR-negative cell populations, such as myeloid cells and
Tcellsabundantlypresent inhumanizedmice,a simpleFc-depen-
dent binding to human FcgRs cannot explain this result, which
we have noted before in classical mouse models (Figure S2;
Table S2) (Schwab et al., 2012b). The binding, however, did not
result in depletion of human cells in humanized mice, excluding
a mechanism in which self-reactive cytotoxic antibodies may
deplete IVIg-bound cell populations (Figure 3C) (Se´ı¨te´ et al.,
2010; von Gunten et al., 2006; von Gunten and Simon, 2008).
Another possible outcome of this widespread binding to immune
cells may be the generation of IVIg target cell immune com-
plexes, which could compete with autoantibody-platelet immune, October 20, 2015 ª2015 The Authors 613
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Figure 4. Influence of IVIg on Human Fcg-
Receptor Expression in Humanized Mice
(A–D) Shown are the relative expression levels
(delta median fluorescence intensities [DMFI]) for
the indicated human FcgRs (FcgRIA, CD64 in A;
FcgRIIIA, CD16 in B; FcgRIIA, CD32A in C; and
FcgRIIB, CD32B in D) on human peripheral blood
cells of humanizedmice before and 6 hr and 7 days
(7d) after infusion of 2.5 g/kg IVIg or PBS. Data are
shown as mean value ± SD of three independent
experiments.
(E and F) Shown is the relative expression level
(DMFI) of human FcgRIIB onmyeloid cells (E) andB
cells (F) in the peripheral blood of humanized mice
2 hr after injection with 150 mg 2B6-N297A anti-
body or with PBS as a control.
(G) Shown is the residual platelet count in hu-
manized NSG-FcRg/ mice 4 hr after injection of
100 mg 6A6-hIgG1. Prior to ITP induction mice
were either pre-treated with PBS, 2.5 g/kg IVIg or
2.5 g/kg IVIg preparations in combination with
150 mg of the anti-FcgRIIB blocking antibody
(clone 2B6).
Data are shown as mean value ± SD of three
independent experiments and statistical anal-
ysis was performed by using a Kruskal-Wallis
and Dunn’s post hoc test. **p % 0.01; ns, not
significant.complexes for binding to activating FcgRs and thereby result in a
block of platelet depletion. Indeed, a general block of the FcgR
system is awidely discussed and plausiblemechanismof IVIg ac-
tivity (Bussel, 2000; Negi et al., 2007; Schwab and Nimmerjahn,
2013). If this was the case, however, one would expect a general
blockade of all IgG-dependent effector functions including
cytotoxic IgG activity under IVIg therapy. To test this, we used a
10-fold-lower dose of the cytotoxic B cell-specific human IgG1
antibody rituximab (10 mg versus 100 mg of the platelet-specific
autoantibody) in the presence or absence of IVIg therapy. Of
note, a 2.5-g/kg dose of IVIgwas not able to blockB cell depletion
while fully blocking autoantibody-mediatedplatelet consumption,
arguing against a general block of activating FcgRs by IVIg infu-
sion (Figures 3D and 3E) and suggesting that IVIg specifically
modulates the activity of the human mononuclear phagocytic
network.614 Cell Reports 13, 610–620, October 20, 2015 ª2015 The AuthorsImpact of IVIg Infusion on Human
FcgR Expression on Monocytes
One repeatedly observed effect of IVIg
infusion in classical mouse models is an
upregulation of the inhibitory FcgRIIB on
innate immune effector cells, which may
result in an increased threshold for cell
activation via immune complexes (Pin-
cetic et al., 2014; Schwab and Nimmer-
jahn, 2013). Such an upregulation of
FcgRIIB on human monocytes may be of
special relevance, as human monocytes,
in contrast to their mouse counterparts,
express only minimal levels of this recep-
tor under steady-state conditions (Luxet al., 2014). Of note, human CD33-positive myeloid cells in the
peripheral blood of humanized mice showed an immediate but
transient upregulation of FcgRIIB upon IVIg infusion, while the
expression level of activating FcgRs remained constant (Figures
4A–4D). These results are consistent with a previous study
demonstrating that FcgRIIB was upregulated on myeloid cells
in chronic inflammatory demyelinating polyneuropathy patients
undergoing IVIg therapy and suggest that IVIg infusion indeed al-
ters the threshold for innate immune effector cell activation on
human cells (Tackenberg et al., 2009). To study if blocking
FcgRIIB function impairs IVIg activity in humanized mice, we in-
jected IVIg in the presence or absence of an FcgRIIB blocking
antibody (2B6). A consecutive staining with the labeled 2B6
antibody demonstrated that the majority of FcgRIIB on B cells
was blocked by this pretreatment, whereas FcgRIIB expression
on monocytes did not show a further decrease in binding,
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Figure 5. Impact of IVIg Sialylation, Modula-
tion of Autoantibody Half-Life, and Genetic
Background on IVIg Activity in Humanized
Mice
(A) Shown is the residual platelet count in human-
ized NSG-FcRg/ mice 4 hr after injection of
100 mg 6A6-hIgG1 or 6A6-hIgG3 autoantibody.
Prior to ITP induction, mice were pre-treated with
PBS, 2.5 g/kg IVIg, or asialylated IVIg (Neur.IVIg)
preparations.
(B) Quantification of human IgG levels [mg/ml] in
the sera of humanized mice as detected by ELISA.
Mice were treated with PBS, 2.5 g/kg IVIg, or
neuraminidase-treated IVIg (Neur.IVIg) 6 hr prior to
serum collection.
(C) Effect of IVIg on autoantibody half-life. Detec-
tion of 6A6-hIgG1 in sera of humanized mice with
active ITP and pre-treated with PBS, 2.5 g/kg IVIg,
or asialylated IVIg (Neur.IVIg). Humanized mice
without 6A6-hIgG1 treatment (no ITP) were used as
controls.
(D) Shown is the residual platelet count in IVIg pre-
treated humanized NSG-FcRg/ mice recon-
stituted with HSCs from donors with the indicated
FcgRIIA and FcgRIIIA allelic variants 4 hr after in-
jection of the 6A6-hIgG1 antibody.
Horizontal lines indicate the median. Bars indicate
the mean value ± SD. Data from at least two in-
dependent experiments are shown and statistical
analysis was performed by using a Kruskal-Wallis
and Dunn’s post hoc test. *p % 0.05, **p % 0.01,
***p% 0.001; ns, not significant.consistent with its very low or absent expression on human
myeloid cells in the peripheral blood during the steady state (Fig-
ures 4E and 4F) (Lux et al., 2014). Consistent with this low initial
FcgRIIB expression level and the rapid platelet depletion upon
autoantibody injection, blocking human FcgRIIB did not impair
IVIg activity in humanized mice (Figure 4G), which is in contrast
to results obtained with blocking mouse FcgRIIB function in a
murine model of ITP (Samuelsson et al., 2001).
Critical Role of Sialic-Acid-Containing IgGGlycovariants
for IVIg Activity In Vivo
There is accumulating evidence that sialic-acid-rich IgGglycosyl-
ation variants within the IVIg preparation may be amajor compo-
nent of its immunomodulatory effect (Anthony et al., 2008a;
Anthony and Ravetch, 2010; Kaneko et al., 2006b; Massoud
et al., 2014; Schwab et al., 2014). However, some recent mouse
in vivo studies and in vitro experiments performed with humanCell Reports 13, 610–620macrophages challenged the concept of
a general requirement of IVIg sialylation
for its immunomodulation of human and
mouse immune cells (Campbell et al.,
2014; Leontyev et al., 2012b; Nagelkerke
et al., 2014). To address this, we gener-
ated asialylated IVIg preparations and
compared their activity to untreated IVIg
preparations. Supporting the concept of
an essential role of this glycosylationvariant within the IVIg preparation for its capacity tomodulate hu-
man phagocytic cell populations in vivo, asialylated IVIg was no
longer able to suppress IgG1 or IgG3 autoantibody-mediated
platelet depletion despite being present at the same level as
IVIg in the serum of humanized mice (Figures 5A and 5B). As
sialic-acid-deficient IVIg also bound to all human cell types in
blood, spleen, and bone marrow while losing its therapeutic ac-
tivity, this further argues against a role of this widespread binding
to immune cells as an underlying mechanism of IVIg activity (Fig-
ures S2A–S2C). Another potential mechanism, which has been
suggested to be responsible for IVIg activity in some, but not
all, studies, is IVIg-mediated interference of autoantibodybinding
to the neonatal Fc receptor (FcRn), which may result in a reduc-
tion of autoantibody half-life (Crow et al., 2011; Hansen and
Balthasar, 2002; Li et al., 2005; Schwab and Nimmerjahn,
2013). This mechanism of action, however, may not be relevant
for our model system, as autoantibody half-life was not affected, October 20, 2015 ª2015 The Authors 615
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Figure 6. Influence of the Human Genetic
Background and Sialic Acid on the Pathway
of IVIg-Mediated Prevention or Resolution
of Established ITP
(A and B) Shown are the residual platelet counts
before (0 hr) and 4 hr after treatment of individual
NSG-FcRg/ mice reconstituted with HSCs from
donors with the indicated FcgRIIA and FcgRIIIA
allelic variants with the 6A6-hIgG1 autoantibody.
Arrows indicate which consecutive treatment reg-
imens (PBS, 2.5 g/kg IVIg, or asialylated IVIg
[Neur.IVIg]) were applied prior to the first and
second induction of ITP by 6A6-hIgG1 injection.
Lines (–) on the x axis indicate a time gap of 7 days.
(C) Quantification of the residual platelet counts at
the first and second ITP induction time points (as
described in A and B) 4 hr after injection of 100 mg
of the anti-platelet antibody 6A6-hIgG1 following
pre-treatment with PBS, IVIg, or Neur.IVIg. Hori-
zontal lines indicate the median.
(D) Shown are the platelet counts in mice with
chronic ITP induced by daily injections of 50 mg of
the platelet-specific antibody 6A6-hIgG1 followed
by treatment with PBS, 2.5 g/kg IVIg, or asialylated
IVIg (Neur.IVIg) preparations at the time point
indicated by the arrow.
Data are shown as mean value ± SD. Data from
more than two independent experiments are
shown, and statistical analysis was performed with
Kruskal-Wallis and Dunn’s post hoc test. *p %
0.05, **p% 0.01, ***p% 0.001; ns, not significant.
See also Figure S3.by IVIgor asialylated IVIg infusionduring theobservationperiod in
this short-termmodel (Figure 5C). Furthermore, the higher level of
autoantibody activity in the presence of the FcgRIIIA-158V allele
had no impact on IVIg activity, consistent with the broad activity
of IVIg in human autoimmune patients (Figure 5D). To exclude
that the genetic heterogeneity within our humanizedmouse pop-
ulation may introduce a bias between experimental groups (IVIg
versus Neur.IVIg treated), we also assessed the activity of IVIg
and neuraminidase-digested IVIg within the same humanized
mouse, carrying the immunesystemof onehumandonor (Figures
6A, 6B, and S3). For this, we induced a thrombocytopenia by a
single injection of the humanized 6A6hIgG1 or 6A6-hIgG3 anti-
body, waited until the platelet counts recovered, and induced a
second ITP with the same amount of the antibody. As shown in
Figures 6A, 6B, and S3, the second autoantibody injection616 Cell Reports 13, 610–620, October 20, 2015 ª2015 The Authorsinduced a thrombocytopenia comparable
to the first injection. In contrast, IVIg, but
not neuraminidase-treated IVIg, pre-
vented platelet depletion within the same
animal. This type of assay was performed
in humanized mice derived from different
human HSC donors, demonstrating that
sialic-acid-rich IgG glycovariants were
critical for IVIg activity independent of
the human FcgRgenotype. Finally, we ad-
dressed the role of IVIg sialylation for the
clinically more relevant therapeutic situa-tion, in which animals are treated at the peak of active ITP and
not preventively. To mimic this situation, we generated a chronic
ITP in humanized mice by daily injections of the humanized 6A6-
IgG1 autoantibody and initiated treatment once platelets were
stably reduced by 80%. As shown in Figure 6D, treatment
with IVIg, but not with neuraminidase-treated IVIg, was able to
induce a rapid recovery of platelet counts, consistent with the
concept of a broad requirement for sialylated IgG glycovariants
for IVIg activity on the background of a human immune system
in vivo.
DISCUSSION
Inbred mouse model systems have been invaluable tools for dis-
secting the molecular and cellular pathways responsible for
mouse IgG activity in vivo (Hogarth and Pietersz, 2012; Pincetic
et al., 2014). Differences between mouse and human antibodies
and Fc receptor systems, however, make it difficult to draw
definitive conclusions with respect to the transferability of these
results to the genetically diverse and outbred human population
(Lux and Nimmerjahn, 2013). While genetic association studies
provide convincing supportive evidence that certain human
FcgR alleles, which confer a higher affinity toward therapeutic
or autoreactive antibodies, result in higher (auto)antibody activ-
ity, respectively, model systems allowing this investigation in
more detail and under well-controlled experimental conditions
have been lacking (Nimmerjahn, 2006; Takai, 2002). To close
this gap, we established a humanized mouse model of auto-
antibody-induced ITP, which responds to IVIg treatment, a clin-
ically relevant standard therapeutic intervention (Bussel, 2006;
Imbach, 2012). These studies revealed that the human autoanti-
body constant region determines autoantibody pathology. Thus,
human IgG1 and IgG3 subclasses were much more potent in
inducing platelet depletion than IgG2 or IgG4 subclasses,
consistent with the higher affinity of IgG1 and IgG3 to human
activating FcgRs (Bruhns et al., 2009; Lux and Nimmerjahn,
2011; Ravetch and Nimmerjahn, 2008). Consistent with this Fc-
dependent effect, humanized mouse colonies generated with
HSCs from donors, carrying different combinations of human
activating Fcg-receptor alleles, demonstrated that the presence
of one high-affinity FcgRIIIA-158V allele results in a higher level of
human autoantibody activity, which is consistent with data from
different human tumor patient cohorts undergoing therapy with
human IgG1 anti-tumor antibodies (Cartron et al., 2002; Muso-
lino et al., 2008; Weng and Levy, 2003; Weng et al., 2010).
Moreover, blocking autoantibody access to human FcgRs and
inactivation of the human mononuclear phagocytic network
interfered with autoantibody activity, firmly establishing a critical
role for cellular FcgRs in human autoantibody activity in vivo.
Interestingly, liver resident macrophages were dispensable for
autoantibody activity, suggesting that either the spleen or the
blood is the site where platelet depletion occurs, which is consis-
tent with data from some classical mouse models of ITP (Bib-
urger et al., 2011; Leontyev et al., 2012a). One important aspect
we could not address in our current model system is the contri-
bution of activating FcgRs expressed on human platelets. In
contrast to human platelets, mouse platelets, which we target
with the humanized 6A6 antibody subclasses, do not express
activating mouse FcgRs or the inhibitory FcgRIIB. To be able
to target human platelets in this model system in the future, we
are in the process of cloning human platelet-specific autoanti-
bodies and enhancing the amount of human platelets.
Apart from human autoantibody activity, we assessed how hu-
man immunomodulatory IVIg preparations suppress autoanti-
body activity under preventive and the clinically most relevant
established autoimmune disease conditions. Studies by a variety
of groups have suggested that IVIg Fab2 or Fc-dependentmech-
anisms may be required for IVIg activity (Negi et al., 2007; Pin-
cetic et al., 2014; Schwab and Nimmerjahn, 2013). In line with
Fab2-dependent mechanisms, some studies suggested that
neutrophil or B cell-specific antibodies in the IVIg preparation
may have a direct cytotoxic or pro-apoptotic activity in vitro
(Se´ı¨te´ et al., 2010; von Gunten et al., 2006; von Gunten andCSimon, 2008). In contrast our study demonstrates that despite
widespread binding of IVIg to human immune cells, this did not
result in cell depletion, suggesting that the level of such cytotoxic
autoantibodies may be too low under clinically relevant doses to
achieve a significant target cell reduction. Moreover, IVIg did not
result in a general blockade of activating FcgRs, evident by a fully
active depletion of human B cells with a 10-fold-lower human
antibody dose under IVIg therapy indicating that a rather specific
modulation of the mononuclear phagocytic system may explain
IVIg activity. Consistent with such a model, we noted an upregu-
lation of FcgRIIB on human myeloid cells 6 hr after IVIg infusion.
Interfering with FcgRIIB function with a monoclonal antibody
blocking immune complex binding to this receptor, however,
was not able to suppress IVIg activity, which may be explained
by differences between FcgRIIB expression on innate immune
effector cells between mice and humans. Thus, on human
myeloid cells in the peripheral blood, FcgRIIB is virtually not
expressed during the steady state. As the platelet depletion in
our acute model system happens immediately upon autoanti-
body injection, the IVIg-mediated upregulation of FcgRIIB we
observed 6 hr after IVIg infusion may be too late to inhibit platelet
depletion under these experimental conditions. Ideally, more
chronic autoimmune diseases may be better suited to study an
impact of FcgRIIB on IVIg activity. Alternatively, humanized
mouse colonies generated from donors with the functionally
impaired FcgRIIB-I232T allele may allow us to address this
important question in the future (Baerenwaldt et al., 2011). Deter-
mining if FcgRIIB upregulation is a mere bystander effect of IVIg
infusion or contributes to the downregulation of autoantibody ac-
tivity will be critical, asmouse studies have led to inconsistent re-
sults with respect to the absolute requirement of the inhibitory
FcgRIIB for IVIg activity, at least in models of ITP (Leontyev
et al., 2012a; Samuelsson et al., 2001).
More recently, compelling evidence for an important role of the
IVIg Fc-fragment and IgG glycoforms rich in terminal sialic acid
residues for IVIg activity was obtained by several groups (An-
thony et al., 2008b, 2011; Kaneko et al., 2006b; Massoud
et al., 2014; Schwab et al., 2012a, 2014; Washburn et al.,
2015), although the general relevance of this finding for the hu-
man system was questioned (Campbell et al., 2014; Leontyev
et al., 2012b; Nagelkerke et al., 2014). With respect to the effect
of IVIg on human immune cells, previous studies were largely
limited to in vitro culture systems, due to the lack of suitable
in vivo model systems (Nagelkerke et al., 2014), resulting in a
rather unclear picture of which pathways are important for the
immunomodulatory activity of IVIg in the human system. Consis-
tent with work in the majority of inbred mouse model systems
and one clinical trial in ITP patients, our present work firmly es-
tablishes that the isolated IVIg Fc-fragment can be sufficient to
ameliorate human autoantibody activity (Bruhns et al., 2003; De-
bre´ et al., 1993; Kaneko et al., 2006a; Schwab and Nimmerjahn,
2013; Semple et al., 2012). Furthermore, asialylated IVIg prepa-
rations lost their ability to prevent the induction or induce the res-
olution of established ITP in humanized mice reconstituted with
human HSCs from a range of human donors with different FcgR
genotypes, demonstrating the potency of sialic-acid-rich IgG
glycovariants as immune modulators of human immune cells
(Pincetic et al., 2014). Moreover, IVIg was able to ameliorateell Reports 13, 610–620, October 20, 2015 ª2015 The Authors 617
ITP irrespective of human activating FcgR alleles, which is
consistent with the widespread clinical efficacy of IVIg therapy
and suggests that the increase of autoantibody affinity to certain
Fcg-receptor alleles can be compensated by clinically relevant
IVIg doses.
Taken together, the results obtained in this humanized mouse
model of ITP suggest that the FcgR pathway may be a central
therapeutic target to suppress human autoantibody activity
and that a potential pathway to improve the immunomodulatory
activity of human IVIg may focus on enhancing sialic acid depen-
dent anti-inflammatory activities (Podolanczuk et al., 2009). With
the establishment of recent protocols to generate highly active
tetrasialylated IVIg preparations or the identification of specific
vaccination strategies allowing the generation of anti-inflamma-
tory sialylated antibodies in vivo, this may pave the way for the
introduction of next-generation anti-inflammatory therapies to
treat human autoimmune diseases (Hess et al., 2013; Washburn
et al., 2015).
EXPERIMENTAL PROCEDURES
Mice
NOD-, SCID-, and gc-deficient mice were obtained from The Jackson Labora-
tory. Mice deficient for the fcer1 gene (FcRg/) were provided by Jeffrey Rav-
etch (Rockefeller University). NOD-SCID/gc-FcRg/ (NSG-FcRg/) mice
were generated by crossing SCID, gc-deficient, and FcRg/ mice to NOD
mice for at least six generations followed by intercrossing to generate NSG-
FcRg/ animals. According to their immunocompromised status, NSG and
NSG-FcRg/ mice were supplied with acidified drinking water (pH 3.0) to
minimize the risk of bacterial infection. All experiments were performed with
humanized mice and non-humanized controls at the age of 12 to 16 weeks.
Mice were kept in the animal facilities of Friedrich-Alexander-University Erlan-
gen-N€urnberg and Rockefeller University under specific-pathogen-free condi-
tions in isolated ventilated cages according to the guidelines of the National
Institutes of Health and the legal requirements of Germany and the United
States.
Generation of Humanized Mice
Newborn NSG-FcRg/ mice were irradiated at the dose of 1.4 Gy and in-
jected intravenously with 30,000–50,000 human HSCs 4–6 hr after irradiation.
HSCs were purified from umbilical cord blood with the written consent of pa-
tients and according to the clinical guidelines of the Friedrich-Alexander-Uni-
versity Erlangen-N€urnberg and the Klinikum F€urth as described previously (Lux
et al., 2014). The reconstitution efficiencywas determined 8 and 12weeks after
transplantation by identification of human cell subsets in whole-blood samples
by flow cytometry.
Antibodies and Reagents
Human 6A6-IgG antibodies were generated as described below. Rituximab
antibodies were produced by transient transfection of HEK293T cells and
subsequent antibody purification as described for human 6A6-IgG antibodies.
Human IVIg was purchased from Biotest AG (Intratect, 100 mg/ml). Fc-frag-
ments were generated by digestion of human IVIg with 0.5 mg/ml papain
and buffer conditions containing 20 mM Tris-HCL + 2 mM L-cysteine (pH
7.0) for 2 hr at 37C. Fab fragments were depleted by protein G purification.
Fc fragments were subsequently separated from non-digested IVIg on a
Superose 12 10/300 GL column (GE Healthcare) via an A¨KTA purifier (GE
Healthcare). Fragment purity was additionally confirmed by SDS-PAGE, fol-
lowed by Coomassie brilliant blue staining. Purity was judged to be greater
than 90%. Neuraminidase, an acetyl-neuraminyl hydrolase (Sialidase), cata-
lyzes the hydrolysis of a2-3, a2-6, and a2-8 linked N-acetyl-neuraminic acid
residues from glycoproteins and oligosaccharides was purchased from New
England Biolabs. IVIg preparations were digested with neuraminidase (50 mg
protein/5U enzyme) using the respective buffer (suggested by the manufac-618 Cell Reports 13, 610–620, October 20, 2015 ª2015 The Authorsturer) at 37C for 20 hr, and successful digestion was confirmed by lectin-
blot analysis (elderberry bark lectin [Sambucus nigra (SNA)], Vector Labora-
tories). For blocking all human Fc receptors, the following antibodies were
used: anti-CD64 (clone 10.1), anti-CD32a/b (clone AT10), and anti-CD16a/b
(clone 3G8). Anti-CD64 and anti-CD16 were purchased from BD Pharmingen.
Anti-CD32 (clone AT10) was provided by M. Glennie (University of Southamp-
ton). A more detailed list of antibodies used for fluorescence-activated cell
sorting and immunofluorescence analysis can be found in Supplemental
Experimental Procedures.
In Vivo ITP Induction and Therapeutic Intervention
ITP was induced by intraperitoneal injection of 100 mg 6A6-hIgG antibodies of
all human IgG subclasses. For the chronic ITP model, 50 mg 6A6-hIgG1 was
injected daily for a period of 4 days. Platelet counts were determined before
and 4 hr after antibody injection of a 1:4 dilution in PBS in an Advia 120 hema-
tology system (Bayer). Platelet counts before antibody injection were set to
100%. For prophylactical intervention, either IVIg (2.5 g/kg), the equimolar
amount of Fc-fragments, asialylated IVIg (2.5 g/kg), or PBS was injected 2 hr
prior to ITP induction. For therapeutic treatment of chronic ITP, either IVIg
(2.5 g/kg), asialylated IVIg (2.5 g/kg), or PBS was injected 48 hr after the first
injection of anti-platelet antibody. Platelet counts were determined daily 4 hr
after each antibody injection. To block all human Fcg receptors or the inhibitory
FcgRIIB alone, the specific antibodies were injected intravenously 2 hr prior to
IVIg application or immediately before IVIg application, respectively.
In Vivo B Cell Depletion Assay and Therapeutic Intervention
B cell depletion in humanized mice was induced by intraperitoneal injection of
10 mg rituximab-IgG1 antibodies. Human B cell counts in peripheral blood
were detected before and 24 hr after antibody injection by flow cytometry. B
cell counts before antibody injection were set to 100%. For prophylactical
intervention, either IVIg (2.5 g/kg) or PBS was injected 2 hr prior to injection
of rituximab-IgG1.
Enzyme-Linked Immunosorbent Assays
Serum of humanized mice was analyzed for the presence of human IgG before
and after treatment of mice with IVIg preparations (for the detection of IVIg, Fc
fragments, and asialylated IVIg) with a human IgG ELISA quantitation kit
(Bethyl Laboratories) following the instructions of the manufacturer. For quan-
tification of total human IgM in the serum of humanized mice, a human IgM
ELISA quantitation kit (Bethyl Laboratories) was used. For the analysis of
platelet-specific antibodies in the sera of humanized mice, murine platelets
from C57BL/6 mice were isolated from peripheral blood and used for coating
96-well ELISA plates as described previously (Kaneko et al., 2006b). After
fixing the platelets by addition of 2% paraformaldehyde (PFA) and subsequent
washing, wells were blocked with PBS/1% BSA for 2 hr at room temperature,
followed by incubation with the serum samples for 1 hr at room temperature.
Finally, bound antibodies were detected by addition of a horseradish peroxi-
dase (HRP)-coupled human IgG-specific antibody (Bethyl Laboratories) and
addition of HRP substrate solution. Optical density was measured with a Ver-
saMax tunable microplate reader (Molecular Devices) at 450 and 650 nm.
Cloning and Production of Antibodies
The heavy-chain variable and first constant region of murine 6A6-antibodies
(described previously; Kaneko et al., 2006b) were fused to heavy-chain con-
stant regions of the human IgG subclasses and cloned into the eukaryotic
pBos expression vector via EcoRI and KpnI restriction sites. For antibody pro-
duction, the murine light chain within a cytomegalovirus promoter region
(pCMV) expression vector was used. Antibodies were produced by transient
transfection of HEK293T cells and subsequent purification of recombinant an-
tibodies from serum-free cell culture supernatant by ammonium sulfate pre-
cipitation and protein G purification (GE Healthcare) as previously described
(Lux et al., 2014).
Isolation of Genomic DNA and Genotyping
Human FcgRIIA-131H/R and FcgRIIIA-158F/V polymorphisms were deter-
mined as described previously (Lux et al., 2014). Briefly, 250 ml of umbilical
cord blood samples was taken and stored at 80C before HSCs were
isolated. Genomic DNA was isolated with the QiaAmp DSP Blood Mini Kit
(Quiagen) following the instructions of the manufacturer. To identify the
FcgRIIA-131H/R and FcgRIIIA-158F/V allelic variants, allele-specific nested
PCRs were performed as described previously (Lux et al., 2014).
Statistical Analysis
Data with unequal variances are depicted as dots with median, and data with
equal variances are depicted as bars indicating the mean value ± SD. For
calculation of statistical significance, the following statistical tests were
applied. For comparison of two groups, samples were calculated using the
Mann-Whitney U test. For comparison of more than two groups, samples
were calculated suing the Kruskal-Wallis test followed by Dunn’s post hoc
test. p values less than 0.5were considered significant. For calculation of linear
correlation (dependence) between two variables, Pearson’s product-moment
correlation coefficient (R2) was used.
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